Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase

Derek Weycker (), Aaron Moynahan, Amanda Silvia and Reiko Sato
Additional contact information
Derek Weycker: Policy Analysis Inc. (PAI)
Aaron Moynahan: Policy Analysis Inc. (PAI)
Amanda Silvia: Policy Analysis Inc. (PAI)
Reiko Sato: Pfizer Inc.

PharmacoEconomics - Open, 2021, vol. 5, issue 2, No 13, 275-284

Abstract: Abstract Background While much is known about the cost of community-acquired pneumonia (CAP) during the acute phase of illness, little is known about the potential attributable cost of CAP thereafter. Objective The aim of this study was to assess long-term attributable costs associated with CAP among adults in US clinical practice. Methods A retrospective matched cohort design and data from a US private healthcare claims repository were employed. In each month during the study period (2011–2016), adults who were hospitalized for CAP in that month (‘CAP patients’) were matched (1:1, without replacement) on demographic, clinical, and healthcare profiles to adults who did not develop CAP in that month (‘comparison patients’). All-cause healthcare expenditures were tallied for the qualifying CAP hospitalization and during the 30-day period post-discharge (collectively, ‘acute phase’), as well as from the end of the acute phase to the end of the 3-year follow-up period (‘long-term phase’). Results The study population included 43,975 matched pairs of CAP patients and comparison patients. Expenditures averaged $33,380 (95% confidence interval [CI] $32,665–$34,161) for the CAP hospitalization and $4568 (95% CI $4385–$4749) during the 30-day period thereafter (vs. $2075 [95% CI $1989–$2167] in total for the comparison patients). During the long-term phase, all-cause expenditures averaged $83,463 (95% CI $81,318–$85,784) for CAP patients versus $51,017 (95% CI $49,553–$52,491) for comparison patients, and thus attributable expenditures during this phase totaled $32,446 (95% CI $29,847–$35,075). The majority of attributable CAP expenditures (53% of $68,319) occurred during the acute phase, while 21%, 14%, and 12% occurred during the first, second, and third years, respectively, after the acute phase. Conclusions Our findings provide additional evidence that the cost of CAP requiring hospitalization is high, and that the impact of CAP extends well beyond the expected time for resolution of acute inflammatory signs.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00240-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:2:d:10.1007_s41669-020-00240-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00240-9

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().